周剂量紫杉类预处理方案的临床研究——紫杉类与铂类药物联合治疗晚期非小细胞肺癌-东南大学学报医学版

周剂量紫杉类预处理方案的临床研究——紫杉类与铂类药物联合治疗晚期非小细胞肺癌

单位：1.东南大学,临床医学院,江苏,南京,210009； 2.江苏省肿瘤医院,肿瘤内科,江苏,南京,210009； 3.东南大学附属中大医院,呼吸内科,江苏,南京,210009

分类号：R979.1, R734.2

出版年·卷·期（页码）：2007·26·第二期（120-123）

摘要：

目的:观察几种周剂量紫杉类化疗预处理方案的安全性以及不良反应,探索最佳周剂量紫杉类预处理方法.方法:紫杉醇50～65mg·m-2静脉滴注＞3h,第1天,每周1次,连续2～3周,联合铂类,28d重复(17例).多西紫杉醇60mg静脉滴注1h,第1、8、15天,联合顺铂60～90mg·m-2,28d重复(9例).采用多种预处理方式.结果:预处理相关的毒副反应包括过敏性反应1例,低钾血症5例,肌无力2例,呃逆1例,水钠潴留2例,感染2例.结论:我们推荐的周剂量紫杉类化疗预处理方案为:(1)使用紫杉醇前12及2h,口服地塞米松2.25～7.5mg;(2)使用多西紫杉醇前1d、当日和第2天口服地塞米松4.5～7.5mg,每日2次.均于化疗前30min予止吐药、H2受体拮抗剂和抗组胺药.

Objective To study the safety and adverse reactiones of the pre-medication for weekly paclitaxel/docetaxel chemotherapy on non-small cell lung cancer,and investigate optimal pre-medication methods.Methods 17 cases were treated with paclitaxel 50-65mg·m-2 every week combining platinum,9 cases with docetaxel 60mg every week combining cisplatin.Each cycle consisted of two or three consecutive weekly taxane followed by 1 week rest.Four pre-medications were attempted.Result The adverse reactions of pre-medications included: hypersensitivity(1 case),hypopotassemia(5 cases),myasthenia(2 cases),hiccup(1 case),retention of water and sodium(2 cases),infection(2 cases).Conclusions Our recommendations for weekly taxane pre-medication are the following: dexamethasone 2.25-7.5mg orally 12 h and 2 h before paclitaxel,antihistaminic and an H2-blocker 30min before paclitaxel;dexamethasone 4.5-7.5mg bid,orally for three consecutive days(d-1,d 0 and d 2),antihistaminic and an H2-blocker 30min before docetaxel.

参考文献：

[1] 孙燕. 内科肿瘤学, 2001
[2] 叶任高, 陆再英. 内科学, 2004
[3] CHEN C H, CHANG J W, LEE C H. Dose-finding and phase 2 study of weekly paclitaxel (taxol) and cisplatin combination in treating chinese patients with advanced nonsmall cell lung cancer. 2005(5)
[4] SCHWARZENBERGER P, THEODOSSIOU C, BARRON S. Dose escalation of docetaxel concomitant with hypofractionated,once weekly chest radiotherapy for non-small-cell lung cancer:a phase Ⅰ study. 2004(4)
[5] KAIRA K, TAKISE A, MINATO K. Phase Ⅱ study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. 2005(4). doi:10.1097/00001813-200504000-00013
[6] JATOI A, STELLA P J, HILLMAN S. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (＞or=65 years of age):a phase Ⅱ north central cancer treatment group study, 2003(5)
[7] MA R, SAN B J. A clinical study on pacitaxel plus cisplatin combined therapy in the treatment of advanced non-small cell lung cancer. Chinese Clinical Oncology2005(2). doi:10.3969/j.issn.1009-0460.2005.02.005
[8] 吴怀中. 肺癌最新TNM分类和分期. 中华肿瘤杂志1998(5)
[9] SCHIFF P B, FANT J, HORWITZ S B. Promotion of microtubule assembly in vitro by taxol. 1979(5698). doi:10.1038/277665a0
[10] CHANG A Y, RUBINS J, ASBURY R. Weekly paclitaxel in advanced non-small cell lung cancer. 2001(4). doi:10.1053/sonc.2001.27607
[11] SEIDMAN A D, HUDIS C A, ALBANEL J. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. 1998(10)
[12] PEREZ E A, VOGEL C L, IRWIN D H. Multicenter phase Ⅱ trial of weekly paclitaxel in women with metastatic breast cancer, 2001(22)
[13] 华新民, 刘枫林, 任宪伟. 应用紫杉类药物前激素预处理的改进及过敏后再输入的探讨. 实用肿瘤学杂志2004(1). doi:10.3969/j.issn.1002-3070.2004.01.016
[14] 吕霞, 苏安, 王馨. 紫杉醇简化预处理方案治疗晚期恶性肿瘤18例次临床报告. 福建医药杂志2002(6). doi:10.3969/j.issn.1002-2600.2002.06.008
[15] 廖美琳. 肺癌, 2003
[16] TSUNODA T, KOIZUMI T, HAYASAKA M. Phase Ⅱ study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. 2004(2). doi:10.1007/s00280-004-0810-5
[17] 吴世凯, 宋三春, 刘晓晴. 泰素帝所致过敏反应一例. 中华肿瘤杂志2001(4)
[18] 胡文彬, 江素玲. 地塞米松不良反应. 中国误诊学杂志2005(11). doi:10.3969/j.issn.1009-6647.2005.11.155

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录